Instil Bio, Inc.

TIL

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$7.66

+$0.08 · +1.06%

Aug 24, 10:19 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

31/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

Expensive

Momentum

Weakening

Sentiment

Mixed

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry: Biotechnology
Sector: Healthcare
Headquarters: US

Market position

Day range

Current $7.66

$7.50$7.665

52-week range

Current $7.66

$5.67$33.833

Open: $7.66
Previous close: $7.58
Volume: 0
Market cap: 51.95M USD
50-day average: $7.4773; +2.44% above average
200-day average: $8.8009; -12.96% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -1.71×
P/B (TTM): 0.48×
P/S (TTM): 0×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%

Financial health

Debt / equity: 0.03×

Financial statements

Income trends

Operating income

−52.91M USD+28.06%

Net income

−71.37M USD+3.73%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Cost of goods sold	534K USD	—	—	5.99M USD	—
Gross profit	−534K USD	—	—	−5.99M USD	—
Research and development	10M USD	11.84M USD	39.6M USD	141.06M USD	107.25M USD
Selling, general, and administrative	27.22M USD	44.21M USD	47.55M USD	62.24M USD	51.31M USD
Operating expenses	52.37M USD	73.54M USD	159.17M USD	200.18M USD	155.56M USD
Interest income	3.86M USD	6.99M USD	8.87M USD	3.66M USD	80K USD
Interest expense	5.83M USD	8.99M USD	5.21M USD	1.88M USD	—
Depreciation and amortization	534K USD	3.61M USD	4.76M USD	5.99M USD	2.75M USD
Operating income	−52.91M USD	−73.54M USD	−159.17M USD	−206.17M USD	−155.56M USD
Net income	−71.37M USD	−74.14M USD	−156.09M USD	−223.18M USD	−156.79M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS: -10.7; FY2025
Latest fiscal-year revenue: 0 USD; FY2025

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$35.00

356.92% upside

Past 12 months12-month forecastHigh $120Average $35.00Low $2.00

TIL news

globenewswire.comAug 13, 2026

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial…

Read source

gurufocus.comAug 3, 2026

Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million

Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop

Read source

seekingalpha.comJul 16, 2026

Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)

Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculative Buy rating upgrade. Q1 revenue reached $71.4M, with Amtagvi generating $60M; the sequential dip was attributed to…

Read source

globenewswire.comJun 1, 2026

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology…

Read source